Trial Results

Protocol
Available Languages: English
Statistical Analysis Plan
Available Languages: English

A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants

Study Identifier:
ALXN1830-HV-105
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN1830
  • Drug: Placebo
Date
Nov 2019 - Jan 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 65 Years
Requirements Information
Sex
Female & Male
Age
18 - 65 Years

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN1830
  • Drug: Placebo
Date
Nov 2019 - Jan 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 65 Years years
Requirements Information

Protocol Summary

This study will evaluate the effects of single ascending doses (SAD) and multiple ascending doses (MAD) of ALXN1830 administered subcutaneously (SC) to healthy adult participants.

Trial Locations

Location
Status
Location
Clinical Trial Site
London, United Kingdom
Status
N/A